Epidemiology of atrial fibrillation: European perspective

Massimo Zoni-Berisso, Fabrizio Lercari, Tiziana Carazza, Stefano Domenicucci, Massimo Zoni-Berisso, Fabrizio Lercari, Tiziana Carazza, Stefano Domenicucci

Abstract

In the last 20 years, atrial fibrillation (AF) has become one of the most important public health problems and a significant cause of increasing health care costs in western countries. The prevalence of AF is increasing due to our greater ability to treat chronic cardiac and noncardiac diseases, and the improved ability to suspect and diagnose AF. At the present time, the prevalence of AF (2%) is double that reported in the last decade. The prevalence of AF varies with age and sex. AF is present in 0.12%-0.16% of those younger than 49 years, in 3.7%-4.2% of those aged 60-70 years, and in 10%-17% of those aged 80 years or older. In addition, it occurs more frequently in males, with a male to female ratio of 1.2:1. The incidence of AF ranges between 0.21 and 0.41 per 1,000 person/years. Permanent AF occurs in approximately 50% of patients, and paroxysmal and persistent AF in 25% each. AF is frequently associated with cardiac disease and comorbidities. The most common concomitant diseases are coronary artery disease, valvular heart disease, and cardiomyopathy. The most common comorbidities are hypertension, diabetes, heart failure, chronic obstructive pulmonary disease, renal failure, stroke, and cognitive disturbance. Paroxysmal AF occurs in younger patients and with a reduced burden of both cardiac disease and comorbidities. Generally, the history of AF is long, burdened by frequent recurrences, and associated with symptoms (in two thirds of patients). Patients with AF have a five-fold and two-fold higher risk of stroke and death, respectively. We estimate that the number of patients with AF in 2030 in Europe will be 14-17 million and the number of new cases of AF per year at 120,000-215,000. Given that AF is associated with significant morbidity and mortality, this increasing number of individuals with AF will have major public health implications.

Keywords: atrial fibrillation; epidemiology; mortality; risk factors; stroke.

Figures

Figure 1
Figure 1
Prevalence of atrial fibrillation in European countries.
Figure 2
Figure 2
Frequency of the different types of atrial fibrillation. Abbreviations: ATRIUM, OutpAtienT RegIstry Upon Morbidity of atrial fibrillation; ISAF, Italian Survey of Atrial Fibrillation management; Euro Heart S, Euro Heart Survey; AFNET, Central Registry of the German Competence Network on Atrial Fibrillation; ATA-AF, AntiThrombotic Agents in Atrial Fibrillation; pts, patients; Parox, paroxysmal; Pers, persistent; Perm, permanent.

References

    1. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Europace. 2006;8:651–745.
    1. Eurostat Methodologies and Working papers Work Session on Demographic Progressions Lisbon, Portugal: April28–302010
    1. Go AS, Hylek EM, Philips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implication for rhythm management and stroke prevention. The AnTicoagulation and RIsk factors in Atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370–2375.
    1. Murphy NF, Simpson CR, Jhund PS, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart. 2007;93:606–612.
    1. Ruskin JN, Singh JP. Atrial fibrillation endpoints: hospitalizations. Heart Rhythm. 2004 Jul;1(Suppl):B31–B35.
    1. Santini M, De Ferrari GM, Pandozi C, et al. FIRE Investigators Atrial fibrillation requiring urgent medical care. Approach and outcome in the various departments of admission. Data from the atrial Fibrillation/Flutter Italian Registry (FIRE) Ital Heart J. 2004;5:205–213.
    1. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274:461–468.
    1. Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace. 2013;15:486–493.
    1. Zoni-Berisso M, Filippi A, Landolina M, et al. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation [From the Italian Survey of Atrial Fibrillation Management (ISAF) Study] Am J Cardiol. 2013;111:705–711.
    1. Piccini JP, Hammil BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries: 1993–2007. Circ Cardiovasc Qual Outcomes. 2012;5:85–93.
    1. Stefansdottir H, Appelund T, Gudnason V, Adnar DO. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projection. Europace. 2011;13:1110–1117.
    1. Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart. 2013;99:1166–1172.
    1. Fitzmaurice DA, Hobbs DR, Jowet S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ. 2007;335:386–391.
    1. Rho RW, Page RL. Asymptomatic atrial fibrillation. Progr Cardiovasc Dis. 2005;48:78–87.
    1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease study. Circulation. 2014;129:837–847.
    1. Gomez-Doblas JJ, Muniz J, Alonso Martin JJ, et al. Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Esp Cardiol. 2014;67(4):259–269.
    1. Kannel WB, Abbot RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018–1022.
    1. Myasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and the implications on the future prevalence. Circulation. 2006;114:119–125.
    1. Meinertz T, Kirch, Rosin L, Pittrow D, Wilich SN, Kirchof P, ATRIUM Investigators Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol. 2011;100:897–905.
    1. Nabauer M, Gerth A, Limbourg T, et al. The Registry of German Competence Network on atrial fibrillation: patient characteristics and initial management. Europace. 2009;11:423–434.
    1. Nieuwlaat R, Capucci A, Camm AJ, et al. European Heart Survey Investigators Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422–2434.
    1. Di Pasquale G, Mathieu G, Maggioni AP, et al. ATA-AF Investigators Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA-AF study. Int J Cardiol. 2013;167:2895–2903.
    1. Levy S, Maarek M, Coumel P, et al. College of French Cardiologists Characterization of different subsets of atrial fibrillation in general practice in France. The ALFA study. Circulation. 1999;99:3028–3035.
    1. Chiang CE, Naditch-Brulé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice. insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5:632–639.
    1. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation. 2012;126:e143–e146.
    1. Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year. Follow up of the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2008;29:1181–1189.
    1. De Sisti A, Leclercq JF, Halimi F, Fiorello P, Bertrand C, Attuel P. Evaluation of time course predicting factors of progression of paroxysmal or persistent atrial fibrillation to permanent atrial fibrillation. Pacing Clin Electrophysiol. 2014;37:345–355.
    1. Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J. 2005;149:489–496.
    1. Jahangir A, Lee V, Friedman PA, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation, A 30-year follow up study. Circulation. 2007;115:3050–3056.
    1. De Voos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation. Clinical correlates and prognosis. J Am Coll Cardiol. 2010;55:725–731.
    1. Self WH, Wasserman BS, McNaughton CD, Darbar D. Evaluating the HATCH score for predicting progression to sustained atrial fibrillation in ED patients with new atrial fibrillation. Am J Emerg Med. 2013;31:792–797.
    1. American Heart Association . Heart and Stroke Statistical Update. Dallas, TX, USA: American Heart Association; 1999. [Accessed May 29, 2014]. Available from: .
    1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
    1. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockolm Cohort of Atrial Fibrillation. Eur Heart J. 2010;31:967–972.
    1. Shroff GR, Solid CA, Herzog CA. Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: a 15-year perspective (1992–2007) JAMA Intern Med. 2013;173:159–160.
    1. Friberg L, Rosenqvist M, Lip GYH. Net clinical benefit of warfarin use in patients with atrial fibrillation: a report of the Swedish Atrial Fibrillation Cohort Study. Circulation. 2012;125:2298–2307.
    1. Cotté FE, Chaize G, Kachaner I, Gaudin AF, Vainchtock A, Durand-Zaleski L. Incidence and cost of stroke and haemorrhage in patients diagnosed with atrial fibrillation. J Stroke Cerebrovasc Dis. 2014;23:73–83.
    1. Ott AO, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hoffman A. Atrial fibrillation and dementia in a population-based study. Stroke. 1997;28:316–321.
    1. Cha MJ, Park H, Lee MH, Cho Y, Choi EK, Oh S. Prevalence and risk factors for silent ischemic stroke in patients with atrial fibrillation as determined by brain magnetic resonance imaging. Am J Cardiol. 2014;113:656–661.
    1. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009;119:2516–2525.
    1. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920–2925.
    1. Mountantonakis SE, Grau-Sepulveda MV, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of Get with the Guidelines – Heart Failure. Circ Heart Fail. 2012;5:191–201.
    1. Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL. Atrial fibrillation and mortality in heart failure: a community study. Circ Heart Fail. 2011;4:740–746.
    1. Andersson T, Magnuson A, Bryngelson IL, et al. All cause mortality in 272186 patients hospitalized with incident atrial fibrillation1995–2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34:1061–1067.
    1. Myasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol. 2007;49:986–992.
    1. Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011;305:2080–2087.
    1. Benerjee A, Taillandier S, Olesen JB, et al. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. Int J Cardiol. 2013;167:2682–2687.
    1. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections of the number of individuals with atrial fibrillation in the European Union from 2000 to 2060. Eur Heart J. 2013;34:2746–2751.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel